Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients

NCT05670054 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Stage IV

Interventions

DRUG: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival

Sponsor

Mansoura University